Paediatric bone marrow mesenchymal stem cells support acute myeloid leukaemia cell survival and enhance chemoresistance via contact‐independent mechanism

Children diagnosed with acute myeloid leukaemia (paediatric AML [pAML]) have limited treatment options and relapse rates due to chemoresistance and refractory disease are over 30%. Current treatment is cytotoxic and in itself has long-lasting harsh side effects. New, less toxic treatments are needed. The bone marrow microenvironment provides chemoprotection to leukaemic cells through cell communication and interaction with mesenchymal stem cells (MSCs), but this is not well defined in pAML. Using primary patient material, we identify a cell contact-independent mechanism of MSC-mediated chemoprotection involving extrinsic soluble factors that is abrogated through inhibition of the JAK/STAT and ERK pathways.

Authors

Institutions

Publication Details

Journal
British Journal of Haematology
Published
2024-11-10
DOI
https://doi.org/10.1111/bjh.19884
Citations
1
Primary Topic
Mesenchymal stem cell research
Type
article
Field-Weighted Citation Impact
0.44

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Paediatric bone marrow mesenchymal stem cells support acute myeloid leukaemia cell survival and enhance chemoresistance via contact‐independent mechanism

Claire Schwab, Karen Keeshan, Cassie J. Clarke, Alison Laing et al.
1 citations
British Journal of Haematology
Mesenchymal stem cell research
0.44
article

Paediatric bone marrow mesenchymal stem cells support acute myeloid leukaemia cell survival and enhance chemoresistance via contact‐independent mechanism

Claire Schwab, Karen Keeshan, Cassie J. Clarke, Alison Laing, Thomas Stevens, Jennifer Cassels, Christine J. Harrison, Brenda Gibson, Ahmed Elmarghany, Arwa A. Alghaith, Aya Gouma, Alexander Winton
article en
1 citations

Abstract

Children diagnosed with acute myeloid leukaemia (paediatric AML [pAML]) have limited treatment options and relapse rates due to chemoresistance and refractory disease are over 30%. Current treatment is cytotoxic and in itself has long-lasting harsh side effects. New, less toxic treatments are needed. The bone marrow microenvironment provides chemoprotection to leukaemic cells through cell communication and interaction with mesenchymal stem cells (MSCs), but this is not well defined in pAML. Using primary patient material, we identify a cell contact-independent mechanism of MSC-mediated chemoprotection involving extrinsic soluble factors that is abrogated through inhibition of the JAK/STAT and ERK pathways.

British Journal of HaematologyVol. 206(3)
Mansoura University (EG), Zagazig University (EG), Royal Hospital for Children (GB), Cancer Research UK (GB), Blood Cancer UK (GB), Queen Elizabeth University Hospital (GB), University of Glasgow (GB), Newcastle University (GB)
Pfizer
Good health and well-being
Openalex Percentile: Top 31%
Mesenchymal stem cell research
0.44
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.